Shandong Sanyuan Biotechnology Co.Ltd. (301206) — Working Capital to Net Assets Ratio
Shandong Sanyuan Biotechnology Co.Ltd. (301206) has a Working Capital to Net Assets ratio of 50.1% as of September 2025. Working capital of CN¥2.16 Billion (current assets of CN¥2.27 Billion minus current liabilities of CN¥107.70 Million) is measured against net assets of CN¥4.31 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See Shandong Sanyuan Biotechnology Co.Ltd. defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Shandong Sanyuan Biotechnology Co.Ltd. Working Capital to Net Assets (2013–2024)
This chart shows how Shandong Sanyuan Biotechnology Co.Ltd.'s Working Capital to Net Assets ratio has evolved across 12 annual periods from 2013 to 2024. As of September 2025, the ratio stands at 50.1%, reflecting working capital of CN¥2.16 Billion against net assets of CN¥4.31 Billion CNY. For the complete balance sheet picture, see Shandong Sanyuan Biotechnology Co.Ltd. assets under control.
Annual Working Capital to Net Assets for Shandong Sanyuan Biotechnology Co.Ltd. (2013–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for Shandong Sanyuan Biotechnology Co.Ltd. from 2013 to 2024, covering 12 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. Check Shandong Sanyuan Biotechnology Co.Ltd. (301206) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 70.0% | CN¥3.14 Billion | CN¥4.49 Billion | CN¥3.39 Billion | CN¥243.67 Million | ▲ +67.9 pp |
| 2023 | 2.2% | CN¥97.62 Million | CN¥4.54 Billion | CN¥321.81 Million | CN¥224.20 Million | ▼ -7.8 pp |
| 2022 | 10.0% | CN¥461.86 Million | CN¥4.62 Billion | CN¥669.37 Million | CN¥207.51 Million | ▼ -13.0 pp |
| 2021 | 23.0% | CN¥240.81 Million | CN¥1.05 Billion | CN¥805.62 Million | CN¥564.81 Million | ▼ -0.5 pp |
| 2020 | 23.5% | CN¥119.78 Million | CN¥509.91 Million | CN¥378.67 Million | CN¥258.89 Million | ▲ +3.5 pp |
| 2019 | 20.0% | CN¥69.52 Million | CN¥348.15 Million | CN¥238.97 Million | CN¥169.46 Million | ▲ +3.8 pp |
| 2018 | 16.2% | CN¥29.08 Million | CN¥179.52 Million | CN¥128.11 Million | CN¥99.03 Million | ▼ -1.4 pp |
| 2017 | 17.6% | CN¥20.38 Million | CN¥115.81 Million | CN¥84.74 Million | CN¥64.36 Million | ▼ -18.3 pp |
| 2016 | 35.9% | CN¥31.11 Million | CN¥86.64 Million | CN¥71.55 Million | CN¥40.44 Million | ▲ +39.4 pp |
| 2015 | -3.5% | CN¥-1.49 Million | CN¥42.30 Million | CN¥23.15 Million | CN¥24.64 Million | ▲ +5.6 pp |
| 2014 | -9.1% | CN¥-2.42 Million | CN¥26.60 Million | CN¥26.98 Million | CN¥29.40 Million | ▼ -47.1 pp |
| 2013 | 38.0% | CN¥9.92 Million | CN¥26.08 Million | CN¥27.63 Million | CN¥17.71 Million | — |